Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7 pseudogene 11 (RPL7P11) is a processed pseudogene in the human genome. It is derived from the functional ribosomal protein L7 gene (RPL7), which encodes a component of the ribosomal 60S subunit involved in protein synthesis. However, RPL7P11 itself does not produce a functional protein product and is not considered to have a known biological function or disease association. Pseudogenes like RPL7P11 are generally regarded as non-coding genomic elements with no therapeutic or biomarker significance. It is designated as a pseudogene based on curated genome annotation databases and gene nomenclature consortia. It is not a therapeutic target, nor does it encode a receptor, enzyme, transporter, or any functional protein; thus, the target is considered "incorrect" in the context of drug discovery or therapeutic biology. No biological functions, disease roles, biomarkers, or interacting drugs are reported for this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 11 (RPL7P11).